Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 1 778.6 INR -1.05%
Market Cap: 90.2B INR
Have any thoughts about
Orchid Pharma Ltd?
Write Note

Orchid Pharma Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orchid Pharma Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Orchid Pharma Ltd
NSE:ORCHPHARMA
Accounts Receivables
â‚ą2B
CAGR 3-Years
13%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Accounts Receivables
â‚ą84.4B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Accounts Receivables
â‚ą55.9B
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
13%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Accounts Receivables
â‚ą129.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
14%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Accounts Receivables
â‚ą17.8B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
4%
M
Mankind Pharma Ltd
NSE:MANKIND
Accounts Receivables
â‚ą8.5B
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orchid Pharma Ltd
Glance View

Market Cap
90.2B INR
Industry
Pharmaceuticals

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

ORCHPHARMA Intrinsic Value
1 261.31 INR
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Orchid Pharma Ltd's Accounts Receivables?
Accounts Receivables
2B INR

Based on the financial report for Mar 31, 2024, Orchid Pharma Ltd's Accounts Receivables amounts to 2B INR.

What is Orchid Pharma Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
10%

Over the last year, the Accounts Receivables growth was -9%. The average annual Accounts Receivables growth rates for Orchid Pharma Ltd have been 13% over the past three years , 10% over the past five years .

Back to Top